Literature DB >> 24971765

Update on high altitude cerebral edema including recent work on the eye.

Gabriel Willmann1, Florian Gekeler, Kai Schommer, Peter Bärtsch.   

Abstract

This review summarizes recent research on high altitude cerebral edema (HACE) and on the eye with focus on the retina and optic nerve as visible brain tissue at high altitude. Hemosiderin deposits in the corpus callosum have been characterized as rather specific long-lasting footprints of HACE, indicating a leak of the blood-brain barrier (BBB) and resulting in microhemorrhages. These are compatible with the concept of increased capillary pressure due to venous outflow limitation as suggested by Wilson et al. There are no human data on the role of vascular permeability in HACE, while animal models of uncertain relevance for human HACE suggest that an impaired integrity of the BBB through VEGF and ROS is more important than hemodynamic changes. Examinations by ultrasound show an inconsistent increase of the optic nerve sheath diameter, whereas unequivocal optic disc swelling (ODS), increased retinal vessel diameter, as well as retinal vessel leakage occur at high altitude. However, whether these morphological changes correlate with symptoms of AMS as a possible precursor of HACE or high altitude headache supporting the concept of venous outflow limitation remains questionable and is discussed in detail in this article.

Entities:  

Mesh:

Year:  2014        PMID: 24971765     DOI: 10.1089/ham.2013.1142

Source DB:  PubMed          Journal:  High Alt Med Biol        ISSN: 1527-0297            Impact factor:   1.981


  9 in total

1.  Proteomic and Morphological Profiling of Mice Ocular Tissue During High-altitude Acclimatization Process: An Animal Study at Lhasa.

Authors:  Jun Hou; Dezhi Zheng; Xudong Wen; Wenjing Xiao; Fei Han; Hongmei Lang; Shiqiang Xiong; Wei Jiang; Yonghe Hu; Mengshan He; Pan Long
Journal:  J Inflamm Res       Date:  2022-05-04

2.  The 2018 Lake Louise Acute Mountain Sickness Score.

Authors:  Robert C Roach; Peter H Hackett; Oswald Oelz; Peter Bärtsch; Andrew M Luks; Martin J MacInnis; J Kenneth Baillie
Journal:  High Alt Med Biol       Date:  2018-03-13       Impact factor: 1.981

3.  Remote ischemic preconditioning delays the onset of acute mountain sickness in normobaric hypoxia.

Authors:  Marc M Berger; Hannah Köhne; Lorenz Hotz; Moritz Hammer; Kai Schommer; Peter Bärtsch; Heimo Mairbäurl
Journal:  Physiol Rep       Date:  2015-03

4.  Retinal changes following rapid ascent to a high-altitude environment.

Authors:  X Tian; B Zhang; Y Jia; C Wang; Q Li
Journal:  Eye (Lond)       Date:  2017-09-15       Impact factor: 3.775

5.  Isolated psychosis during exposure to very high and extreme altitude - characterisation of a new medical entity.

Authors:  Katharina Hüfner; Hermann Brugger; Eva Kuster; Franziska Dünsser; Agnieszka E Stawinoga; Rachel Turner; Iztok Tomazin; Barbara Sperner-Unterweger
Journal:  Psychol Med       Date:  2017-12-05       Impact factor: 7.723

Review 6.  The role of post-translational modifications in driving abnormal cardiovascular complications at high altitude.

Authors:  Jun Hou; Xudong Wen; Pan Long; Shiqiang Xiong; Hanxiong Liu; Lin Cai; Haoyu Deng; Zhen Zhang
Journal:  Front Cardiovasc Med       Date:  2022-09-14

Review 7.  [Research progress on the effects of plateau hypoxia on blood-brain barrier structure and drug permeability].

Authors:  Yidan Ding; Wenbin Li; Rong Wang; Jianchun Zhang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2019-12-25

8.  H2S Regulates Hypobaric Hypoxia-Induced Early Glio-Vascular Dysfunction and Neuro-Pathophysiological Effects.

Authors:  Gaurav Kumar; Aastha Chhabra; Shalini Mishra; Haroon Kalam; Dhiraj Kumar; Ramniwas Meena; Yasmin Ahmad; Kalpana Bhargava; Dipti N Prasad; Manish Sharma
Journal:  EBioMedicine       Date:  2016-03-28       Impact factor: 8.143

Review 9.  Retinal venous pressure: the role of endothelin.

Authors:  Josef Flammer; Katarzyna Konieczka
Journal:  EPMA J       Date:  2015-10-26       Impact factor: 6.543

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.